Hepatitis C infection, an infection of the liver by the hepatitis C virus, is a major global health concern, affecting millions.
More Than a Cure, a Path to Improvement: Hepatitis C Treatment
read more
Global Liver Institute
COVID-19
GLOBAL LIVER INSTITUTE
COVID-19
Understanding the New EASL-EASD-EASO Guidelines on MASLD
Clinical practice guidelines are evidence-based recommendations developed through systematic review and consensus to help healthcare providers and patients make informed decisions about the most appropriate treatment options for specific health conditions.
GLI Celebrates FDA Approval of Livdelzi®, an Option in Personalizing PBC Treatment
Global Liver Institute (GLI) celebrates the expansion of treatment options for patients with primary biliary cholangitis (PBC) after the U.S. Food and Drug Administration decided to provide accelerated approval of Gilead Science’s seladelpar (Livdelzi®) for primary biliary cholangitis (PBC).
Catch Up on Possible End-of-Year Legislative Action and FY 2025 Appropriations Updates – Liver Health Policy Update
Congress is entering the August recess period. Nevertheless, patients are increasingly signaling to policymakers their frustration related to coverage challenges and over-zealous utilization management practices such as non-medical switching and other barriers to care. And appropriations bills are out for FY 2025!
Fatty Liver Disease Affects Millions, But the Future for Treatment Remains Brighter Than Ever – Fatty Liver Disease News
The recent FDA approval of resmetirom, which offers hope for those with moderate-to-advanced liver scarring, marks a breakthrough in treatment.
Growing Awareness between Alcohol and Cancer Risk – Liver Cancer News
Thank you for reading Liver Cancer News! Liver cancer is associated with low five-year survival rates, often due to late-stage diagnosis of the disease.
FDA’s New Rare Disease Innovation Hub may accelerate rare liver disease treatment – Pediatric & Rare Liver Diseases News
Ipsen Pharmaceuticals has just shared exciting news for rare liver disease patients with cholestasis.
Available Today! New Patient Assistance & Provider Resources – Fatty Liver Disease News
Trauma-informed, patient-led consultations to build trust and enhance medical care are important to clinical care for liver health, Dr. Julia Wattacheril, Director of the MASLD Program at Columbia’s Center for Liver Disease and Transplantation, has emphasized.
Global Liver Institute and National Alliance for Caregiving Provide Recommendations to the Centers for Medicare & Medicaid Services and Centers for Medicare and Medicaid Innovation’s Increasing Organ Transplant Access (IOTA) Model
Based on our shared knowledge and experience, Global Liver Institute and National Alliance for Caregiving are proud to collaborate in providing recommendations to CMS and the Centers for Medicare and Medicaid Innovation (CMMI) that we believe will improve the proposed Increasing Organ Transplant Access (IOTA) Model
Obesity legislation on the move, GLI continues to fight for access to NASH/MASH treatments – Liver Health Policy Update
The House Ways and Means Committee marked up obesity legislation, moving the ball forward for Congress to act on coverage for Medicare beneficiaries. GLI solicits signatures on a petition to insurers to provide access to NASH/MASH treatment.
New this month: Copayment assistance for certain genetic/metabolic diseases and a second-line PBC therapy! – Pediatric & Rare Liver Diseases News
We are honored to have had the opportunity to represent the rare liver diseases community at the Alpha-1 Foundation National Conference in Miami, Florida. The weekend was filled with transformative research and thought-provoking conversations.
Indications of Advancements and a Promising Outlook – Liver Cancer News
A new AI-driven blood test has been developed to improve the detection of liver cancer. Currently, up to 60% of liver cancers are not diagnosed until advanced stages, with a survival rate of just 20%.